Last reviewed · How we verify
Pacritinib and Clarithromycin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Pacritinib and Clarithromycin (Pacritinib and Clarithromycin) — CTI BioPharma.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pacritinib and Clarithromycin TARGET | Pacritinib and Clarithromycin | CTI BioPharma | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pacritinib and Clarithromycin CI watch — RSS
- Pacritinib and Clarithromycin CI watch — Atom
- Pacritinib and Clarithromycin CI watch — JSON
- Pacritinib and Clarithromycin alone — RSS
Cite this brief
Drug Landscape (2026). Pacritinib and Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/pacritinib-and-clarithromycin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab